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REVIEW
Abstract: Interventions to reduce mortality and disability in older people are vital. Aspirin is
cheap and effective and known to prevent cardiovascular and cerebrovascular disease, many
cancers, and Alzheimer dementia. The widespread use of aspirin in older people is limited by
its gastrointestinal side effects. Understanding age-related changes in gastrointestinal
physiology that could put older people at risk of the side effects of aspirin may direct strategies
to improve tolerance and hence lead to greater numbers of older people being able to take this
effective intervention.
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Introduction
As the population ages, clinical and cost effective strategies to increase lifespan whilst
reducing disability are becoming a major public health agenda. The cyclooxygenase
inhibitor aspirin has the potential to be such a strategy, as it is a simple, cheap
intervention that is increasingly recognized as preventing a wide range of diseases
associated with significant morbidity, and as a result will ensure healthy life into
older age.
Evidence for the benefits of aspirin is now so overwhelming that strategies to
deliver it to as many older people as possible are a health promotion priority. Many
cancers, strokes, myocardial infarctions, and cases of Alzheimer dementia might be
prevented if more older people could benefit from the risk reductions of aspirin.
Evidence supporting the benefits of aspirin
Aspirin is one of the most frequently prescribed medications for older people
(Somerville et al 1986). It is taken to control inflammation in arthritis, but more
importantly has been shown in meta-analyses to reduce events in those at risk from
cardiovascular or cerebrovascular disease
 (Antiplatelet Trialists Collaborative 2002;
Hayden et al 2002). There is also emerging evidence that aspirin use protects against
Alzheimer dementia and a wide range of cancers including breast, esophageal,
prostate, colorectal, and lung carcinomas (Dubois et al 1998; Smith et al 2000; Bardou
et al 2004).
Mathematical modeling confirms that the beneficial effects of aspirin are
potentially so great that encouraging low-dose aspirin use in all 50-year-old subjects
would reduce disability and double the chances of living a healthy life into old age
(Morgan 2003). Many studies are now suggesting that the benefits of long-term low-
dose aspirin outweigh the risks (Eidelman et al 2003). In the elderly, these benefits
are to an extent similar to, and often greater than, that observed in younger age
groups (Dornbrook et al 2003). However, the studies necessary to acquire such data
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in older age groups will require huge numbers such as that
seen in the ongoing Aspirin in Reducing Events in the
Elderly (ASPREE) study with 15 000 subjects aged over 70
being followed for 5 years (Nelson et al 2003).
Despite the acknowledged benefits of aspirin, a cross-
sectional population survey found only 7.1% were taking
aspirin as a primary preventative measure (Trinder et al
2003). Furthermore, of those prescribed aspirin for secondary
prevention, 8% were no longer taking it at 6-month follow
up, presumably because of side effects (Eagle et al 2004).
Gastrointestinal adverse effects of
aspirin
The widespread use of aspirin by older people has
historically been limited as many develop abdominal side
effects. Almost 50% of those prescribed aspirin for
secondary prevention report gastrointestinal symptoms after
just 2 weeks of use (Laheij et al 2001; Niv et al 2005) and
almost one-third of aspirin users have endoscopically visible
lesions within one hour of ingestion (Hawkey et al 1991;
Cole et al 1999). Symptoms are recognized as a poor
predictor for gastrointestinal lesions with 48% of
asymptomatic aspirin users having lesions visible at
endoscopy.
Aspirin can lead to adverse gastrointestinal effects
ranging from dyspepsia with endoscopically normal gastric
mucosa, asymptomatic and symptomatic lesions such as
erosions and ulcers, and complications of ulcers including
bleeding and perforation. Although these gastrointestinal
effects are dose dependant, even lower doses of aspirin are
being increasingly recognized as a cause of gastrointestinal
bleeding (Stack et al 2002).
It is controversial, however, whether simply being old
makes you more susceptible to aspirin-induced gastro-
intestinal damage or whether comorbidity, comedications,
and past history are more important predictors of toxicity
than age and perhaps more relevant to therapeutic decision
making in this population (Solomon and Gurwtiz 1997).
Risk factors for aspirin-induced gastrointestinal compli-
cations are shown in Table 1.
Developing strategies to improve
tolerability of aspirin
Gastrointestinal side effects of aspirin occur more frequently
in older people (Aalykke 2001). Therefore strategies to
improve tolerability might be directed in two ways: at those
specific physiological abnormalities that identify individuals
who are less able to tolerate aspirin irrespective of their age,
and at age-related changes in gastrointestinal physiology
that might predict why older people tolerate aspirin less well
compared with younger age groups (Table 2). This review
will focus primarily on this second strategy.
Strategies to improve tolerability: the
eradication of Helicobacter pylori
Many changes in gastrointestinal physiology once thought
to be primary effects of aging have been reexamined since
the discovery of the microorganism Helicobacter pylori
(Kateralis et al 1993; Feldman et al 1996). Infection with
H. pylori itself induces changes in gastrointestinal
physiology, which is of relevance when it is appreciated
that in the Western world infection rates increase with age,
with up to 80% of 80-year-old subjects infected (Marshall
1994).
Both aspirin use and H. pylori infection cause peptic
ulcers, but whether the incidence is greater when both are
present is unclear (Voutilainen et al 2001). H. pylori and
aspirin are independent risk factors for ulceration in all age
groups (Lanas et al 2002), however, studies specifically
involving older people suggest that there may be a
synergistic effect on risk (Ng et al 2000; Seinela and
Ahvenainen 2000).
Table 1 Risk factors for aspirin-induced gastrointestinal
complications
￿ Advancing age
￿ Female sex
￿ History of peptic ulcer disease
￿ Type and dose of NSAID
￿ Duration of use
￿ Use of combinations of NSAIDs
￿ Concomitant use of drugs such as steroids or anticoagulants
Adapted from Aalykke et al (2001); Gallerani et al (2004).
Table 2 Potential strategies to improve tolerability of aspirin
in older people
Helicobacter pylori eradication
Coprescription:
– With PPI
– With prostaglandin analog
Improve mucosal protective mechanisms
– Reverse the age-associated decline in mucus thickness
– Improve secretion of mucosal protective molecules, eg, TFF2
Reduce contact time by reversing the age-associated decline in gastric
emptying
Abbreviations: PPI, proton pump inhibitor; TTF2, trefoil factor family 2.Clinical Interventions in Aging 2006:1(1) 35
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Low doses of aspirin induced endoscopically visible
upper gastrointestinal mucosal damage more frequently
in H. pylori positive subjects (50%) compared with 16% of
H. pylori negative volunteers (Feldman et al 2001).
Furthermore, eradication of H. pylori reduces damage
caused by low doses of aspirin and recurrence of ulcers
during aspirin use (McCarthy 1998) and improves
adaptability of the gastrointestinal tract to aspirin (Konteruk
et al 1997, 1998). Unfortunately, H. pylori eradication will
not always improve aspirin tolerability, as gastrointestinal
symptoms, ulcers, and their complications are associated
with aspirin use in those with, and without, H. pylori
infection (Seinela and Ahvenainen 2000).
Despite this, it would seem pragmatic to recommend
eradication of H. pylori infection prior to commencing long-
term aspirin treatment. Whether or not this approach is
appropriate in all older people, irrespective of symptoms,
or only in those with gastrointestinal symptoms or a history
of peptic ulceration (NICE 2005) requires large studies in
older people and should include evaluation of aspirin
tolerance after H. pylori eradication (Figure 1).
Structural changes with age in the
upper gastrointestinal tract could affect
tolerance of aspirin
Gastrointestinal transit time, in particular gastric emptying,
is slower in older people (Brogna et al 1999), which
potentially increases exposure of the gastric mucosa to
ingested drugs. Such direct toxic effects provide the rationale
for the use of enteric-coated aspirin. Theoretically,
influencing the time of exposure to, or the formulation of,
aspirin preparations, or reversing the age-associated decline
in gastrointestinal transit time, may influence the ability of
older people to tolerate aspirin.
Atrophy of the gastric mucosa incidence increases with
age (James 2000) partly because of the increased prevalence
of H. pylori in older people. Gastric atrophy results in smaller
volumes of less acidic gastric juice in the stomach lumen.
This reduced ability to dilute ingested drugs will potentially
increase the risk of direct gastrointestinal toxic side effects.
Further study is required to determine whether widespread
H. pylori eradication programmes would decrease gastric
atrophy prevalence in older people and allow better tolerance
of aspirin.
Improving tolerance of aspirin by
addressing age-related changes in
gastrointestinal physiology
There is limited research examining age-related changes in
the human upper gastrointestinal tract that might explain
why older people tolerate aspirin less well. What is currently
known about changes in physiology in the older stomach
and duodenum is summarized in Figure 2. An understanding
of these changes in gastric physiology with age could direct
interventions that lead to improved tolerance.
In the human gastrointestinal tract there is a balance
between aggressive factors (gastric acid and pepsin) and
mucosal protective mechanisms (mucus and bicarbonate).
Current evidence does not suggest that the increase in
dyspeptic symptoms or ulceration in older people taking
Older person 
Gastrointestinal symptoms/history of 
gastrointestinal disease 
yes no
H. pylori
positive
H. pylori
negative
Commence
aspirin
Eradicate H. pylori 
Develop
gastrointestinal side 
effects
Commence of aspirin with PPI 
H. pylori status 
Figure 1 Proposed algorithm to improve gastrointestinal tolerance of aspirin in
older people. Abbreviations: PPI, proton pump inhibitor.
Luminal effects
↓ transit time
↓ gastric emptying
↑ gastric atrophy
↓ volume of gastric juice
↓ dilution of noxious agents
↓ acid production
↓ ability to activate acid dependant medications
↓ altered bioavailability of modified release preparations
Mucosal protection
↓ bicarbonate
↓ mucus protection
↓ prostaglandin
Repair processes
↓ reparative capacity of the epithelium
↓ blood supply
Figure 2 Age-related changes in gastrointestinal physiology.Clinical Interventions in Aging 2006:1(1) 36
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aspirin is related to an age-related increase in the aggressive
factors: gastric acid or pepsin. Gastric acid secretion may
be reduced in older people due to the increase in gastric
atrophy, and pepsin output is also lower (Feldman et al
1996). However, age-related deficiencies in the ability of
the mucosa to protect and repair itself have been
documented, and any additional depletion due to medication
such as aspirin will further increase mucosal vulnerability
(Guslandi et al 1999).
Gastrointestinal mucosal protective molecules such as
prostaglandins decline with advancing age (Cryer, Lee, et
al 1992; Cryer, Redfern, et al 1992; Goto et al 1992; Lee
and Feldman 1994). Prostaglandins stimulate protective
mechanisms such as mucus and bicarbonate whilst aspirin
inhibits prostaglandin production and causes gastric damage
(Sababi et al 1995). The lower levels of prostaglandins in
the gastric mucosa of older people makes them more
susceptible to damage by a further reduction in prostaglandin
synthesis caused by aspirin.
The first line of mucosal protection from exogenous
toxins and luminal acid and pepsin is the mucus gel layer.
Studies have shown both a quantitative reduction in mucus
production with age and impaired quality of the mucus
(Corfield et al 1993; Farinati et al 1993; Newton, Jordan et
al 2000), and as a result an increased susceptibility to damage
by aspirin (Corfield et al 1993).
The ability of the gastric mucosa to protect itself by
repelling toxins is independently decreased in association
with H. pylori induced gastritis and NSAID use (Goddard
et al 1987; Spychal et al 1990) and also with aging
(Hackelsberger et al 1998). It is not clear whether these
factors work synergistically.
There is also an age-related decline in the ability of the
gastrointestinal mucosa to neutralize luminal acid by
bicarbonate secretion (Kim et al 1990; Lee 1997; Feldman
et al 1998; Guslandi et al 1999). The older stomach is also
less able to repair itself after damage (Lee et al 1998; Liu et
al 1998), which when taken with the antithrombotic effects
of aspirin may account for gastrointestinal side effects.
Control of the repair processes is poorly understood but does
have the potential to be manipulated (Majumdar et al 1997).
Trefoil proteins are a family of mucosal repair proteins
thought to be important in gastrointestinal protection (May
and Westley 1997). Trefoil factor family 1 (TFF1) and TFF2
are expressed in the stomach and TFF2 and TFF3 are
expressed in the duodenum. TFF1 is intimately associated
with gastric mucus (Newton, Allen, et al 2000) and gastric
concentrations of TFF2 show a circadian variation
 (Semple
et al 2001) increasing dramatically at night. Recent work
by our group has shown that the nocturnal peak of mucosally
protective TFF2 is lower and earlier in older people (Johns
et al 2005), and manipulating the nocturnal increase of
cytoprotective TFF2 or encouraging patients to take aspirin
at night when the mucosal protective mechanisms are
optimal may improve tolerability.
In animals, a reduction in basal gastric blood flow (Lee
1996) and an attenuation of gastric blood flow in response
to injury has been observed with age (Gronbech and Lacy
1994; Miyake et al 1996), though this is controversial (Taha
1993). If there are reductions in gastric blood flow in older
people, coprescription of the vasodilator nitric oxide with
aspirin (NO-NSAID) may have potential (Wallace et al
1995).
Strategies known to reduce
gastrointestinal complications of aspirin
in older people
Studies carried out specifically in older age groups have
shown in both acute and chronic users of aspirin, that
concomitant use of a proton pump inhibitor (PPI) reduces
the risk of gastrointestinal bleeding (odds ratio [OR] 1.12
chronic, 1.05, acute) (Pilotto et al 2003) and risk of peptic
ulcer disease (Pilotto et al 2004).
This benefit from PPI coprescription with aspirin is
greater than with either the prostaglandin analog misoprostol
(OR 1.91) and H2 blockers (OR 2.26). This has prompted
the recommendation that PPI cotreatment is advisable in
symptomatic older patients who need treatment with aspirin.
However, whether a similar approach is appropriate for
primary prevention of complications in asymptomatic older
people requiring aspirin needs study.
In addition, although the studies confirm that both PPI
and misoprostol are effective at reducing the risk of ulcer
recurrence (Goldstein et al 2004), this does not guide clinical
practice when confronted with a patient who simply
develops gastrointestinal symptoms (rather than compli-
cations) after commencing aspirin.
Some have suggested that in high-risk patients with
aspirin-associated peptic ulcer disease, conversion to other
antiplatelet therapies such as clopidogrel may be
appropriate. However, studies suggest that complication
rates with clopidogrel are no better than continuation of
aspirin alone (Ng et al 2004), with studies confirming that
aspirin plus PPI is superior to clopidogrel in the prevention
of recurrence (Chan et al 2005).Clinical Interventions in Aging 2006:1(1) 37
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Patients taking long-term, low-dose aspirin who have
had ulcer complications respond to acid suppressive
treatments such as a PPI after eradication of H. pylori (Lai
et al 2002), but eradication alone may be superior to the use
of a PPI (Chan et al 2001). It should be remembered that
coprescription of acid suppressive treatments with aspirin
to improve tolerability in older people is unlikely to be the
whole answer as physiologically there is no age-related
increase in acid.
Future directions
Damage to the gastrointestinal mucosa is related to aspirin
dose (Moore et al 1989, 1991) and lower doses of aspirin
have fewer side effects (Serrano et al 2002). Therefore, it
may be that some aspirin is better than no aspirin, and studies
in older age groups would determine whether smaller doses
of aspirin could be tolerated and give some, if not all, of the
benefits obtained with larger doses in younger age groups.
In the past, treatment of those who developed adverse side
effects was terminated. The evidence for the use of aspirin
is now so overwhelming that we need to consider how to
give some aspirin to as many people as possible.
There are huge implications for allowing greater
numbers of older people to benefit from taking aspirin for
prevention of cardiovascular and cerebrovascular disease,
Alzheimer dementia, and cancer. Defining the underlying
age-related changes in physiology that make the older
gastrointestinal tract susceptible to damage will identify
targets for therapy. Reducing deficiencies in mucosal repair
proteins, such as growth factors and trefoil proteins, may
improve the reparative process. Delineating the pathways
of action of these molecules in older people is therefore
important. Conceptually simple strategies such as reducing
the prevalence of gastric atrophy or reversing the age-
associated decline in gastric emptying may also be effective.
Conclusion
Aging of the stomach and duodenum is an important but
poorly understood area of gerontology. In older people, the
major causes of mortality and morbidity are cardiovascular
and cerebrovascular diseases, gastrointestinal cancers, and
dementia. Understanding how aspirin reduces risk in these
diseases and whether or not older people are intrinsically at
risk of side effects because of age-related changes in
gastrointestinal physiology should allow greater numbers
of older people to benefit from the risk reductions associated
with taking aspirin. Research in this area could be translated
directly into the clinical setting and potentially make a real
impact upon the quality of life of older people.
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